Natera/$NTRA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Ticker

$NTRA
Primary listing

Industry

Biotechnology

Employees

4,429

ISIN

US6323071042

Natera Metrics

BasicAdvanced
$22B
-
-$1.48
1.79
-

What the Analysts think about Natera

Analyst ratings (Buy, Hold, Sell) for Natera stock.

Bulls say / Bears say

Natera's revenue has grown at a compounded annual rate of 40.9% over the past five years, indicating strong market demand for its products. (stockstory.org)
The company has secured Medicare coverage for its Signatera™ genome-based assay, potentially expanding its market reach and revenue streams. (businesswire.com)
Analysts have set an average 12-month price target of $185.56 for Natera, suggesting a potential upside of approximately 14.71% from its current price. (stockanalysis.com)
Natera's price-to-sales ratio of 11.4x is higher than many peers in the biotech industry, raising concerns about overvaluation. (simplywall.st)
The company reported an operating margin of -50.92%, indicating significant challenges in achieving profitability. (gurufocus.com)
Despite strong revenue growth, Natera's return on equity stands at -80.57%, reflecting inefficiencies in generating returns for shareholders. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Natera Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Natera Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NTRA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs